CMPX · Healthcare
Compass Therapeutics Inc
20/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$411M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About COMPASS THERAPEUTICS INC
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets…
Who's behind the signal
Every informed buyer we can see on CMPX, across all three feeds.
Hedge funds · 5
Tudor Investment (Paul Tudor Jones)
New position
D.E. Shaw & Co
Increased +28%
Citadel Advisors
Increased +583%
AQR Capital Management
Increased +29%
Millennium Management (Englander)
Decreased −73%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
COMPASS THERAPEUTICS INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
1
New positions
3
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+28%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+583%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+29%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−73%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to COMPASS THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COMPASS THERAPEUTICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订